Health Affairs, 25, no. 5 (2006): 1202-1203 doi: 10.1377/hlthaff.25.5.1202 © 2006 by Project HOPE	New Online   House Health Reform Bill   Paying for Reform   Vetting AHIP's Report   HIV/AIDS Costs   Brief: Insurance Reform   HA Blog Top 10

This Article Full Text (HTML) Reprint (PDF) Submit a response to this article Alert me when this article is cited Alert me when Comments are posted Alert me if a correction is posted Services E-mail this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Personal Archive Download to Citation Manager Reprints & Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Iglehart, J. K. Search for Related Content PubMed PubMed Citation Articles by Iglehart, J. K. Related Collections Insurance Coverage Medicare Pharmaceuticals Research And Technology Consumer Issues

From the Editor

Biotech Drugs Come Of Age; Policymakers Take Notice

IN THE VAST U.S. MEDICAL ECONOMY, with annual expenditures of $2 trillion, spending on biotechnology products represents a minuscule fraction, but it is growing rapidly. In 2005, revenues totaled $50.7 billion, an increase of 15.8 percent over the previous year, according to Ernst and Young, which tracks the industry. The largest biotechnology companies—Amgen, Genentech, Genzyme, and Gilead—enjoyed particularly robust growth. However, the industry as a whole recorded a net loss of $4.1 billion, which underscores the reality that drug development is a risky business. On the public policy front, the biotech industry—indeed, all of the . . . [Full Text of this Article]

John K. Iglehart, Founding Editor

                      What's this?